Drug Profile
Research programme: autoimmune disorder therapeutics - Biogen
Alternative Names: RORγT inhibitors - BiogenLatest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Reata Pharmaceuticals
- Developer Biogen
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Inflammation